Related Experiment Video

Updated: Mar 22, 2026

Live Imaging of Antifungal Activity by Human Primary Neutrophils and Monocytes in Response to A. fumigatus
12:29

Live Imaging of Antifungal Activity by Human Primary Neutrophils and Monocytes in Response to A. fumigatus

Published on: April 19, 2017

10.8K

Micafungin as primary antifungal prophylaxis in patients presenting with acute myeloid leukemia

G Venton1, H Adam2, J Colle1

  • 1Inserm, UMR1090 TAGC, 13288 Marseille, France; Aix-Marseille université, UMR1090 TAGC, 13288 Marseille, France; Service d'hématologie et de thérapie cellulaire AP-HM, hôpital de la Conception, Marseille, France.

Medecine Et Maladies Infectieuses
|April 30, 2016
PubMed
Abstract

Insights

Micafungin effectively prevented invasive fungal infections in acute myeloid leukemia patients during chemotherapy. This antifungal agent demonstrated a favorable safety profile with minimal toxicity in the study cohort.

Area of Science:

  • Hematology
  • Infectious Diseases
  • Pharmacology

Background:

  • Acute myeloid leukemia (AML) patients undergoing induction chemotherapy are highly susceptible to invasive fungal infections (IFIs).
  • Prophylaxis against IFIs is crucial to reduce morbidity and mortality in this immunocompromised population.
  • Micafungin, an echinocandin antifungal, is a potential agent for IFI prophylaxis.

Purpose of the Study:

  • To evaluate the efficacy and safety of micafungin for preventing IFIs.
  • To assess micafungin's role in high-risk patients with hematological disorders receiving induction chemotherapy for AML.

Main Methods:

  • A prospective, observational, single-center study included 41 AML patients.
  • Micafungin was administered intravenously once daily starting with induction chemotherapy until neutropenia resolved.
  • Patients were monitored for IFIs and adverse events for three months post-treatment.

Main Results:

  • No cases of Candida or Aspergillus infections were observed during micafungin treatment and neutropenic phase.
  • No breakthrough IFIs occurred in the three-month follow-up period after micafungin discontinuation.
  • One patient experienced grade III-IV hepatic and ionic toxicities, indicating a good safety profile.

Conclusions:

  • Micafungin is a safe and effective prophylactic agent against IFIs in AML patients undergoing induction chemotherapy.
  • The favorable safety profile and efficacy make micafungin a compelling option for IFI prevention in high-risk hematological patients.
Keywords:
Acute myeloid leukemiaAspergillusLeucémie aiguë myéloïdeMicafunginMicafungine

More Related Videos

Intra-Peritoneal Transplantation for Generating Acute Myeloid Leukemia in Mice10:02

Intra-Peritoneal Transplantation for Generating Acute Myeloid Leukemia in Mice

Published on: January 6, 2023

2.6K
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.9K

Related Concept Videos

Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to...
20
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
62